Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants ≥18 years of age at Screening in Study B7981040. Adolescents (12 to \<18 years of age at Screening in the parent study) are also eligible for this study if approved by the local IRB/EC and regulatory health authority.
Participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in Study B7981040
The BL visit/first dose in Study B7981041 must be within 30 days after the week 52 visit in Study B7981040
You may not be if
Participant met the parent study (Study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event
Any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation
Clareo Health | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
